RKRoy Raheb Khelo

Roy Raheb Khelo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roy Raheb Khelo has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neurogenic irritable bowel syndrome? Long-term resolution of chronic gastrointestinal stress following vagus nerve microvascular decompression: illustrative case

    by James Tanner McMahon, Roy Raheb Khelo, Brent D. Weinberg, Nicholas M. Boulis

    BACKGROUND: Microvascular decompression (MVD) is a well-established treatment for compressive cranial neuralgias such as trigeminal neuralgia and hemifacial spasm. The vagus nerve (cranial nerve [CN] X), with its extensive parasympathetic innervation to the gastrointestinal (GI) system, has less clearly defined neuropathic symptomatology, and MVD of CN X has only been reported once. The authors report a unique case of treatment-refractory GI distress that resolved completely following CN X MVD. OBSERVATIONS: A 32-year-old male with a 13-year history of hemifacial spasm also experienced chronic, debilitating GI distress characterized by sudden, painful abdominal cramping and diarrhea. Despite extensive workup, including three colonoscopies, no clear etiology was found. During MVD for his facial nerve, a large vertebral artery loop was incidentally found significantly displacing CN X. Both nerves were decompressed. Both the patient’s hemifacial spasms and GI symptoms resolved immediately, and this has persisted for more than 5 years of follow-up. LESSONS: While vagal injury (including intentionally via vagotomy) results in gastroparesis, the authors propose that chronic CN X compression may induce a “hyperactive rhizopathy” resulting in symptoms of overactive peristalsis. CN X compression may be an underrecognized, reversible etiology of chronic GI distress, and clinicians should consider the possibility of neurovascular conflict in this patient population. https://thejns.org/doi/10.3171/CASE2688

  • Open Access

    Intrathecal Administration of Riluzole in Amyotrophic Lateral Sclerosis

    by Alexandre Bétourné, Pavlos Texakalidis, Roy Raheb Khelo, Melissa Campbell, Saud A. Sadiq, Nicholas M. Boulis

    BACKGROUND AND OBJECTIVES: Riluzole is the only treatment known to improve survival in amyotrophic lateral sclerosis (ALS) patients. However, its efficacy and dosing are limited by hepatic toxicity and interindividual pharmacokinetic variability. Recent experimental studies in hounds have shown that continuous intrathecal (IT) administration of riluzole is well tolerated and achieves significantly higher spinal cord tissue levels. We report the first 2 human ALS cases treated with IT riluzole. METHODS: A catheter was inserted into the lumbar cistern and advanced to the midcervical region under fluoroscopic guidance and connected to a subcutaneous pump. Therapy was initiated at 0.1 mg/h of riluzole. The infusion rate was gradually increased until it reached a maximum of 4.8 mg/d. RESULTS: The 2 patients tolerated dose escalation and treatment for over 2 years without apparent motor or sensory complications. Patients reported no asthenia, a central side effect often reported as a reason to abandon oral therapy. CONCLUSION: This is the first report of chronic IT riluzole infusion in humans at a dose found to be safe in canines. A phase 1 study is planned to establish the maximum tolerated human dose, followed by a randomized placebo-controlled trial to determine the safety and tolerability of IT riluzole in patients with ALS.

  • The Future of Chemogenetics for the Treatment of Spasticity

    by Kelly Poth, Roy Raheb Khelo, Anthony Donsante, Nicholas M. Boulis

    The management of spasticity poses a significant challenge for both physicians and patients. This condition, often characterized by increased muscle tone, clonus, and muscle spasms, can be painful, disrupt daily activities, and increases the risk of injuries. First-line treatment for spasticity includes oral medications, such as baclofen, but these drugs can have significant side effects due to inhibitory effects on neural circuits, such as drowsiness and dizziness. Surgical approaches can be applied to patients for whom oral medications fail. However, these treatments can have life-threatening side effects or are irreversible. An emerging technology, chemogenetics, has the potential to provide targeted relief of spasticity, combining a non-destructive surgical approach with the convenience of an oral medication. This Current Opinion describes the current treatment approaches for spasticity, the pathophysiology of this condition, the current state of chemogenetics, and how this technology may be applied to patients with poorly controlled spasticity. Although the use of this approach is at an early developmental stage, we believe that it shows great promise.